Загрузка...
New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
In non-small cell lung cancer (NSCLC), the most frequent oncogenic mutation in western countries is KRAS, for which, however, there remains no clinically approved targeted therapies. Recent progress on high biological heterogeneity including diverse KRAS point mutations, varying dependence on mutant...
Сохранить в:
| Опубликовано в: : | Front Oncol |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6773824/ https://ncbi.nlm.nih.gov/pubmed/31612108 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00953 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|